Integrated Oncology

For Patients

Prepare for visits with your doctor or a genetic counselor by learning about testing.

Working with Integrated Oncology


Integrated Oncology Highlights

Integrated Oncology now offers the DAKO PD-L1 IHC 22C3 pharmDxTM test.  This test was recently FDA approved as a companion diagnostic assay to aid in identifying metastatic NSCLC patients for treatment with KEYTRUDA® (pembrolizumab).  Learn more...

Physicians - Use of the ICD-10-CM code set is now required.  Effective October 1, 2015. LEARN MORE about LabCorp's additional resources.

VistaSeqSM Hereditary Cancer Panel - an assessment of genetic mutations within a panel of 27 genes known to be associated with hereditary cancer syndromes.  Learn more about VistaSeq.

BRCAssure® BRCA 1 and 2 Analysis. Learn more about BRCAssure.  

ProsignaTM Breast Cancer Prognostic Gene Signature Assay, which is based on the PAM50 gene signature, is an FDA 510(k) cleared assay to assess a patient’s risk of distant recurrence of disease.   Learn more...

IntelliGEN® Oncology Therapeutic Panel (NGS) assay provides an assessment of targetable mutations within a panel of cancer genes known to be involved in the development, progression and/or treatment of cancers.  Learn more…